AtriCure (NASDAQ:ATRC) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

AtriCure (NASDAQ:ATRC) had its price objective upped by stock analysts at JPMorgan Chase & Co. from $40.00 to $51.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 20.40% from the company’s previous close.

Other analysts also recently issued reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $60.00 price target on shares of AtriCure in a report on Monday. Oppenheimer lifted their price target on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Needham & Company LLC lifted their price target on shares of AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Canaccord Genuity Group lifted their price objective on shares of AtriCure from $53.00 to $61.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, UBS Group lifted their price objective on shares of AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $46.44.

AtriCure Stock Up 2.0 %

Shares of ATRC stock opened at $42.36 on Tuesday. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -51.04 and a beta of 1.46. AtriCure has a one year low of $18.94 and a one year high of $43.11. The company’s fifty day moving average price is $35.39 and its 200-day moving average price is $31.09. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59.

Institutional Investors Weigh In On AtriCure

Large investors have recently modified their holdings of the business. Arcadia Investment Management Corp MI acquired a new position in AtriCure during the 3rd quarter valued at approximately $28,000. Heck Capital Advisors LLC acquired a new position in AtriCure during the 4th quarter valued at approximately $60,000. Venturi Wealth Management LLC increased its stake in AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock valued at $69,000 after purchasing an additional 2,100 shares in the last quarter. KBC Group NV increased its stake in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after purchasing an additional 932 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of AtriCure in the 4th quarter valued at $89,000. Institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.